Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance.
Miklos W, Pelivan K, Kowol CR, Pirker C, Dornetshuber-Fleiss R, Spitzwieser M, Englinger B, van Schoonhoven S, Cichna-Markl M, Koellensperger G, Keppler BK, Berger W, Heffeter P. Miklos W, et al. Among authors: englinger b. Cancer Lett. 2015 May 28;361(1):112-20. doi: 10.1016/j.canlet.2015.02.049. Epub 2015 Mar 5. Cancer Lett. 2015. PMID: 25749419
Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.
Englinger B, Lötsch D, Pirker C, Mohr T, van Schoonhoven S, Boidol B, Lardeau CH, Spitzwieser M, Szabó P, Heffeter P, Lang I, Cichna-Markl M, Grasl-Kraupp B, Marian B, Grusch M, Kubicek S, Szakács G, Berger W. Englinger B, et al. Oncotarget. 2016 Aug 2;7(31):50161-50179. doi: 10.18632/oncotarget.10324. Oncotarget. 2016. PMID: 27367030 Free PMC article.
Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.
Englinger B, Kallus S, Senkiv J, Heilos D, Gabler L, van Schoonhoven S, Terenzi A, Moser P, Pirker C, Timelthaler G, Jäger W, Kowol CR, Heffeter P, Grusch M, Berger W. Englinger B, et al. J Exp Clin Cancer Res. 2017 Sep 7;36(1):122. doi: 10.1186/s13046-017-0592-3. J Exp Clin Cancer Res. 2017. PMID: 28882160 Free PMC article.
Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins.
Heilos D, Röhrl C, Pirker C, Englinger B, Baier D, Mohr T, Schwaiger M, Iqbal SM, van Schoonhoven S, Klavins K, Eberhart T, Windberger U, Taibon J, Sturm S, Stuppner H, Koellensperger G, Dornetshuber-Fleiss R, Jäger W, Lemmens-Gruber R, Berger W. Heilos D, et al. Among authors: englinger b. Oncotarget. 2018 May 22;9(39):25661-25680. doi: 10.18632/oncotarget.25432. eCollection 2018 May 22. Oncotarget. 2018. PMID: 29876015 Free PMC article.
33 results